Literature DB >> 15025561

Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene.

Lee Ann Johnston1, Suat Erdogan, York Fong Cheung, Michael Sullivan, Rachael Barber, Martin J Lynch, George S Baillie, Gino Van Heeke, David R Adams, Elaine Huston, Miles D Houslay.   

Abstract

PDE4A7 is an isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene that fails to hydrolyse cAMP and whose transcripts are widely expressed. Removal of either the N- or C-terminal unique portions of PDE4A7 did not reconstitute catalytic activity, showing that they did not exert a chronic inhibitory effect. A chimera (Hyb2), formed by swapping the unique N-terminal portion of PDE4A7 with that of the active PDE4A4C form, was not catalytically active. However, one formed (Hyb1) by swapping the unique C-terminal portion of PDE4A7 with that common to all active PDE4 isoforms was catalytically active. Compared with the active PDE4A4B isoform, Hyb1 exhibited a similar K(m) value for cAMP and IC50 value for rolipram inhibition, but was less sensitive to inhibition by Ro-20-1724 and denbufylline, and considerably more sensitive to thermal denaturation. The unique C-terminal region of PDE4A7 was unable to support an active catalytic unit, whereas its unique N-terminal region can. The N-terminal portion of the PDE4 catalytic unit is essential for catalytic activity and can be supplied by either highly conserved sequence found in active PDE4 isoforms from all four PDE4 subfamilies or the unique N-terminal portion of PDE4A7. A discrete portion of the conserved C-terminal region in active PDE4A isoforms underpins their aberrant migration on SDS/PAGE. Unlike active PDE4A isoforms, PDE4A7 is exclusively localized to the P1 particulate fraction in cells. A region located within the C-terminal portion of active PDE4 isoforms prevents such exclusive targeting. Three functional regions in PDE4A isoforms are identified, which influence catalytic activity, subcellular targeting and conformational status.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15025561      PMCID: PMC1224194          DOI: 10.1042/BJ20031662

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  71 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 2.  A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.

Authors:  R E Weishaar; M H Cain; J A Bristol
Journal:  J Med Chem       Date:  1985-05       Impact factor: 7.446

3.  Multiple cyclic nucleotide phosphodiesterase activities from rat brain.

Authors:  W J Thompson; M M Appleman
Journal:  Biochemistry       Date:  1971-01-19       Impact factor: 3.162

4.  Antagonism of WT1 activity by protein self-association.

Authors:  P Moffett; W Bruening; H Nakagama; N Bardeesy; D Housman; D E Housman; J Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

5.  A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes.

Authors:  R J Marchmont; M D Houslay
Journal:  Biochem J       Date:  1980-05-01       Impact factor: 3.857

6.  Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase.

Authors:  G P Livi; P Kmetz; M M McHale; L B Cieslinski; G M Sathe; D P Taylor; R L Davis; T J Torphy; J M Balcarek
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

7.  Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation.

Authors:  C Sette; M Conti
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

8.  The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram.

Authors:  E Huston; L Pooley; P Julien; G Scotland; I McPhee; M Sullivan; G Bolger; M D Houslay
Journal:  J Biol Chem       Date:  1996-12-06       Impact factor: 5.157

9.  Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes.

Authors:  J V Swinnen; D R Joseph; M Conti
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

10.  Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain.

Authors:  S L Jin; J V Swinnen; M Conti
Journal:  J Biol Chem       Date:  1992-09-15       Impact factor: 5.157

View more
  7 in total

Review 1.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

2.  Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.

Authors:  Yun-Feng Li; Yu-Fang Cheng; Ying Huang; Marco Conti; Steven P Wilson; James M O'Donnell; Han-Ting Zhang
Journal:  J Neurosci       Date:  2011-01-05       Impact factor: 6.167

3.  Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function.

Authors:  Hannah Murdoch; Suryakiran Vadrevu; Anke Prinz; Allan J Dunlop; Enno Klussmann; Graeme B Bolger; James C Norman; Miles D Houslay
Journal:  J Cell Sci       Date:  2011-06-07       Impact factor: 5.285

4.  β-Adrenergic receptor stimulation increases surface NKCC2 expression in rat thick ascending limbs in a process inhibited by phosphodiesterase 4.

Authors:  Mohammed Z Haque; Paulo S Caceres; Pablo A Ortiz
Journal:  Am J Physiol Renal Physiol       Date:  2012-08-29

5.  Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change.

Authors:  Kirsty F Mackenzie; Emma C Topping; Bozena Bugaj-Gaweda; Chengjun Deng; York-Fong Cheung; Aileen E Olsen; Cecil R Stockard; Lisa High Mitchell; George S Baillie; William E Grizzle; Michael De Vivo; Miles D Houslay; Daguang Wang; Graeme B Bolger
Journal:  Biochem J       Date:  2008-04-15       Impact factor: 3.857

Review 6.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

7.  Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains.

Authors:  Graeme B Bolger; Allan J Dunlop; Dong Meng; Jon P Day; Enno Klussmann; George S Baillie; David R Adams; Miles D Houslay
Journal:  Cell Signal       Date:  2014-12-27       Impact factor: 4.315

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.